Glaxosmithkline (GSK)

Company name:Glaxosmithkline Plc
Company Description:A group engaged in the creation; discovery; development; manufacture and marketing of pharmaceutical and consumer health-related products
EPIC:GSKTrading Currency:GBX
Market Sector:FE10ISIN:GB0009252882
Market Segment:SET1Share Type:DE
WWW Address:http://www.gsk.com/Description:ORD 25P
Industry Sector:PHARMACEUTICALS & BIOTECHNOLOGY
 Price Price Change [%] Bid Ask Open High Low Volume
 1,753.00 images.advfn.com/imagesnew/2/us/up 2.8 [0.16] 1,753.20 1,753.80 1,752.60 1,768.60 1,749.60 9,217,074
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 87,027.01 4,964.46 0.19 73.70 80.00 23.79 4.56 1,796.40 - 1,429.80

Glaxosmithkline Key Figures

Key Figures
(at previous day's close)
Market Cap.87,027.01m
Shares In Issue4,964.46m
Prev. Close1,750.20
PE Ratio23.79 
Dividend Yield4.56%
EPS - basic73.70p
Dividend PS80.00p
Dividend Cover0.92 
Cash Flow PS169.63p
Return On Equity (ROE)83.10%
Operating Margin13.13%
PEG Factor0.18 
EPS Growth Rate134.71%
Dividends PS Growth Rate-%
Net Debt50,520.00m
Gross Gearing93.68%
Quick Assets15,066.00m
Net Working Capital-1,949.00m
Intangibles / Fixed Assets61.27%
Turnover PS620.83p
Pre-Tax Profit PS81.54p
Retained Profit PS-6.12p
Cash PS78.03p
Net Cash PS-375.01p
Net Tangible Asset Value PS *-375.29p
Net Asset Value PS73.97p
Spread0.60 (0.03%) 

Glaxosmithkline Balance Sheet

%1$s Balance Sheet
LSE:GSK:Liabilities+EQLSE:GSK:Assets

Share Price Performance

Share Price Performance
Sample Period HighLow
1 week1,768.601,690.00
4 weeks1,768.601,677.80
12 weeks1,796.401,612.40
1 year1,796.401,429.80

Share Price Chart (5 years)

Share Price Chart (5 years)

Glaxosmithkline Historic Returns

%1$s Historic Returns
Giorni da oggi OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week1,709.0044.002.571,690.006.741,725.50
4 weeks1,732.2020.801.201,677.807.001,722.50
12 weeks1,646.20106.806.491,612.408.341,705.06
26 weeks1,579.00174.0011.021,561.208.221,676.96
1 year1,478.00275.0018.611,429.808.381,603.69
3 years1,481.00272.0018.371,236.408.931,532.46
5 years1,391.50361.5025.981,227.509.001,505.16

Glaxosmithkline Key Management Ratios

DEEPER ANALYSIS

Glaxosmithkline Investment Ratios

%1$s Investment Ratios
(Market value analysis) at previous day's close
PQ Ratio29.58 
PE Ratio23.79 
Tobin's Q Ratio 1.52 
Tobin's Q Ratio (excl. intangibles)2.55 
Dividend Yield4.56%
Market-to-Book Ratio19.96 
Price-to-Pre-Tax Profit PS21.50 
Price-to-Retained Profit PS-286.27 
Price-to-Cash Flow PS10.33 
Price-to-Sales PS2.82 
Price-to-Net Tangible Asset Value PS-4.50 
Price-to-Cash PS22.46 
Net Working Capital PS-39.26 
Price Pct to Working Capital PS-44.65%
Earnings Yield4.20%
Average PE35.41 
Years in average5 
PE to PE average67.18%

Glaxosmithkline Financial Ratios

%1$s Financial Ratios
(Leverage Ratios)
Debt Ratio89.68%
Debt-to-Equity Ratio8.69 
Debt-to-Equity Ratio (excl. Intgbl)-1.65 
Debt-to-Equity Market Value0.37 
Net Gearing87.00%
Net Gearing (excl. Intangibles)144.03%
Gross Gearing93.68%
Gross Gearing (excl. Intangibles)155.08%
Gearing Under 1 Year38.73%
Gearing Under 1 Year (excl. Intgbl)64.12%
Assets/Equity15.81 
Cash/Equity105.50 
(Liquidity Ratios)
Net Working Capital to Total Assets-3.36%
Current Ratio0.91 
Quick Ratio (Acid Test)0.67 
Liquidity Ratio0.17 
Cash & Equiv/Current Assets18.86%
(Solvency Ratios)
Enterprise Value114,368.01m
CFO/Sales0.27 
CFO/Attributable Profit2.32 
CFO/Assets0.15 
CFO/Debt0.15 
Total Debt/Equity Market Value0.63 
Total Debt/Sales1.76 
Total Debt/Pre-Tax Profit13.44 
Total Debt54,394.00m
Total Debt/Net Current Assets-27.91%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth57.68%
5 yr Compound Earnings Growth5.16%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs9 
Beta coefficients
Beta (60-Mnth)Beta (36-Mnth)
0.1874-0.0055

Glaxosmithkline Operating Ratios

%1$s Operating Ratios
(Profitability Ratios)
Return On Capital Employed (ROCE)11.38%
Return On Assets (ROA)6.33%
Net Profit Margin11.75%
Assets Turnover0.54 
Return On Equity (ROE)83.10%
Return On Investment (ROI)11.08%
Dividend Payout Ratio108.55%
Plowback Ratio-8.55%
Growth from Plowback Ratio-14.43%
Net Income Of Revenues-0.99%
(Asset Utilisation Multiples)
Shareholders Equity Turnover14.36 
Fixed Assets Turnover0.83 
Current Assets Turnover1.54 
Net Working Capital Turnover 
Inventory Turnover5.59 
(Other Operating Ratios)
Total Assets-to-Sales1.86 
Debtors-to-Sales33.41%
Debt Collection Period121.94Days

Glaxosmithkline Dividends

%1$s Dividends
Announcement DateTypeCurr.Dividend AmountPeriod StartPeriod EndEx DateRecord DatePayment DateTotal Dividend Amount
06 Feb 2019FinalGBX23.0012/31/201712/31/201802/21/201902/22/201904/11/201980.00
31 Oct 2018QuarterlyGBX19.0012/31/201712/31/201811/15/201811/16/201801/10/2019-
25 Jul 2018QuarterlyGBX19.0012/31/201712/31/201808/09/201808/10/201810/11/2018-
25 Apr 2018QuarterlyGBX19.0012/31/201712/31/201805/10/201805/11/201807/12/2018-
07 Feb 2018FinalGBX23.0012/31/201612/31/201702/22/201802/23/201804/12/201880.00
25 Oct 2017QuarterlyGBX19.0012/31/201612/31/201711/09/201711/10/201701/11/2018-
26 Jul 2017QuarterlyGBX19.0012/31/201612/31/201708/10/201708/11/201710/12/2017-
26 Apr 2017QuarterlyGBX19.0012/31/201612/31/201705/11/201705/12/201707/13/2017-
08 Feb 2017FinalGBX23.0012/31/201512/31/201602/23/201702/24/201704/13/201780.00
26 Oct 2016QuarterlyGBX19.0012/31/201512/31/201611/03/201611/04/201601/12/2017-
27 Jul 2016QuarterlyGBX19.0012/31/201512/31/201608/11/201608/12/201610/13/2016-
27 Apr 2016QuarterlyGBX19.0012/31/201512/31/201605/12/201605/13/201607/14/2016-
03 Feb 2016FinalGBX23.0012/31/201412/31/201502/18/201602/19/201604/14/2016100.00
03 Feb 2016SpecialGBX20.0012/31/201412/31/201502/18/201602/19/201604/14/2016-
19 Oct 2015QuarterlyGBX19.0012/31/201412/31/201511/12/201511/13/201501/14/2016-
29 Jul 2015QuarterlyGBX19.0012/31/201412/31/201508/13/201508/14/201510/01/2015-
06 May 2015QuarterlyGBX19.0012/31/201412/31/201505/14/201505/15/201507/09/2015-
04 Feb 2015FinalGBX23.0012/31/201312/31/201402/19/201502/20/201504/09/201580.00
22 Oct 2014QuarterlyGBX19.0012/31/201312/31/201411/06/201411/07/201401/08/2015-
24 Jul 2014QuarterlyGBX19.0012/31/201312/31/201408/06/201408/08/201410/02/2014-
30 Apr 2014QuarterlyGBX19.0012/31/201312/31/201405/14/201405/16/201407/10/2014-
05 Feb 2014FinalGBX23.0012/31/201212/31/201302/19/201402/21/201404/10/201478.00
23 Oct 2013QuarterlyGBX19.0012/31/201212/31/201311/13/201311/15/201301/09/2014-
24 Jul 2013QuarterlyGBX18.0012/31/201212/31/201308/07/201308/09/201310/03/2013-
24 Apr 2013QuarterlyGBX18.0012/31/201212/31/201305/08/201305/10/201307/11/2013-
06 Feb 2013FinalGBX22.0012/31/201112/31/201202/20/201302/22/201304/11/201374.00
31 Oct 2012QuarterlyGBX18.0012/31/201112/31/201211/14/201211/16/201201/03/2013-
25 Jul 2012QuarterlyGBX17.0012/31/201112/31/201208/08/201208/10/201210/04/2012-
25 Apr 2012QuarterlyGBX17.0012/31/201112/31/201205/09/201205/11/201207/05/2012-
07 Feb 2012SpecialGBX5.0012/31/201012/31/201102/15/201202/17/201204/12/2012-
07 Feb 2012FinalGBX21.0012/31/201012/31/201102/15/201202/17/201204/12/201275.00
26 Oct 2011InterimGBX17.0012/31/201012/31/201111/02/201111/04/201101/05/2012-
26 Jul 2011InterimGBX16.0012/31/201012/31/201108/03/201108/05/201110/06/2011-
27 Apr 2011InterimGBX16.0012/31/201012/31/201105/04/201105/06/201107/07/2011-
03 Feb 2011FinalGBX19.0012/31/200912/31/201002/09/201102/11/201104/07/201165.00
21 Oct 2010InterimGBX16.0012/31/200912/31/201010/27/201010/29/201001/06/2011-
21 Jul 2010InterimGBX15.0012/31/200912/31/201007/28/201007/30/201010/07/2010-
28 Apr 2010InterimGBX15.0012/31/200912/31/201005/05/201005/07/201007/08/2010-
04 Feb 2010FinalGBX18.0012/31/200812/31/200902/10/201002/12/201004/08/201061.00
29 Oct 2009QuarterlyGBX15.0012/31/200812/31/200911/04/200909/06/200901/07/2010-
30 Jul 2009QuarterlyGBX14.0012/31/200812/31/200907/31/200907/31/200910/08/200928.00
22 Apr 2009QuarterlyGBX14.0012/31/200812/31/200904/29/200905/01/200907/09/2009-
05 Feb 2009FinalGBX17.0012/31/200712/31/200802/11/200902/13/200904/09/200957.00
22 Oct 2008QuarterlyGBX14.0012/31/200712/31/200810/29/200810/31/200801/09/2008-
07 Feb 2008FinalGBX13.0012/31/200612/31/200702/13/200802/15/200804/10/200853.00
25 Jul 2007QuarterlyGBX12.0012/31/200612/31/200708/01/200708/03/200710/11/2007-
24 Apr 2007QuarterlyGBX12.0012/31/200612/31/200705/02/200705/04/200707/12/2007-
08 Feb 2007QuarterlyGBX14.0012/31/200512/31/200602/14/200602/16/200604/12/2007-
08 Feb 2007FinalGBX-12/31/200512/31/2006---48.00
26 Oct 2006QuarterlyGBX12.0012/31/200512/31/200611/01/200611/03/200601/04/2007-
26 Jul 2006QuarterlyGBX11.0012/31/200512/31/200608/02/200608/04/200610/05/2006-
27 Apr 2006QuarterlyGBX11.0012/31/200512/31/200605/10/200605/12/200607/06/2006-
08 Feb 2006FinalGBX14.0012/31/200412/31/200502/15/200602/17/200604/06/200644.00
27 Oct 2005QuarterlyGBX10.0012/31/200412/31/200511/02/200511/04/200501/05/2006-
29 Jul 2005QuarterlyGBX10.0012/31/200412/31/200508/03/200508/05/200510/06/2005-
28 Apr 2005QuarterlyGBX10.0012/31/200412/31/200505/11/200505/13/200507/07/2005-
10 Feb 2005FinalGBX12.0012/31/200312/31/200402/16/200502/18/200504/07/200542.00
28 Oct 2004QuarterlyGBX10.0012/31/200312/31/200411/03/200411/05/200401/06/2005-
27 Jul 2004QuarterlyGBX10.0012/31/200312/31/200408/04/200408/06/200409/30/2004-
27 Jul 2004QuarterlyGBX10.0012/31/200312/31/200405/12/200405/14/200407/01/2004-
12 Feb 2004FinalGBX14.0012/31/200212/31/200302/18/200402/20/200404/15/200441.00
11 Feb 2004QuarterlyGBX9.0012/31/200212/31/200310/29/200310/31/200301/06/2004-
23 Jul 2003QuarterlyGBX9.0012/31/200212/31/200307/30/200308/01/200310/02/2003-
30 Apr 2003QuarterlyGBX9.0012/31/200212/31/200305/07/200305/09/200307/03/2003-
12 Feb 2003FinalGBX13.0012/31/200112/31/200202/19/200302/21/200304/17/200340.00
23 Oct 2002QuarterlyGBX9.0003/30/200209/30/200210/30/200211/01/200201/03/2003-
24 Jul 2002QuarterlyGBX9.0012/30/200106/30/200207/31/200208/02/200210/03/2002-
25 Apr 2002QuarterlyGBX9.0010/01/200103/31/200205/01/200205/03/200207/04/2002-
14 Feb 2002FinalGBX12.0012/31/200012/31/200102/20/200202/22/200204/18/200239.00
23 Oct 2001QuarterlyGBX9.0009/30/200009/30/200110/31/200111/02/200101/03/2002-
24 Jul 2001QuarterlyGBX9.0006/30/200006/30/200108/01/200108/03/200110/04/2001-
24 Apr 2001QuarterlyGBX9.0003/31/200003/31/200105/02/200105/04/200107/05/2001-
13 Dec 2000FinalGBX23.0012/31/199912/31/200012/18/200012/22/200004/17/200138.00
27 Jul 2000InterimGBX15.0012/30/199906/30/200008/07/200008/11/200010/16/2000-
16 Feb 2000FinalGBX22.0012/31/199812/31/199902/28/200003/03/200005/25/200037.00
29 Jul 1999InterimGBX15.0012/30/199806/30/199908/09/199908/13/199910/01/1999-
18 Feb 1999FinalGBX21.0012/31/199712/31/199803/01/199903/05/199905/20/199936.00

Glaxosmithkline Fundamentals

Profit and Loss Account
 31 Dec 2015 (GBP)31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)
turnover23,923.00100.00%27,889.00100.00%30,186.00100.00%30,821.00100.00%m
pre tax profit10,526.0044.00%1,939.006.95%3,525.0011.68%4,048.0013.13%m
attributable profit8,422.0035.20%912.003.27%1,532.005.08%3,623.0011.75%m
retained profit4,548.0019.01%-3,938.00-14.12%-2,374.00-7.86%-304.00-0.99%m
eps - basic (p)174.30 18.80 31.40 73.70 
eps - diluted (p)172.30 18.60 31.00 72.90 
dividends per share100.00 80.00 80.00 80.00 

Glaxosmithkline Balance Sheet

Balance Sheet
 31 Dec 2015 (GBP)31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)
LSE:GSK:Liabilities+EQLSE:GSK:AssetsLSE:GSK:Liabilities+EQLSE:GSK:AssetsLSE:GSK:Liabilities+EQLSE:GSK:AssetsLSE:GSK:Liabilities+EQLSE:GSK:Assets
 31 Dec 2015 (GBP)31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)
ASSETS
fixed assets fixed assets9,668.0018.09%10,808.0018.29%10,860.0019.26%11,058.0019.04%m
intangibles intangibles21,834.0040.85%24,741.0041.88%23,296.0041.32%22,991.0039.59%m
fixed investments fixed investments2,652.004.96%2,692.004.56%2,668.004.73%3,475.005.98%m
current assets - other current assets - other46.000.09%215.000.36%113.000.20%653.001.12%m
stocks stocks4,716.008.82%5,102.008.64%5,557.009.86%5,476.009.43%m
debtors debtors8,700.0016.28%10,626.0017.99%10,054.0017.83%10,539.0018.15%m
cash & securities cash & securities5,830.0010.91%4,897.008.29%3,833.006.80%3,874.006.67%m
TOTAL53,446.00100%59,081.00100%56,381.00100%58,066.00100%m
LIABILITIES
creditors - short creditors - short13,417.0025.10%19,001.0032.16%26,569.0047.12%22,491.0038.73%m
creditors - long creditors - long31,151.0058.28%35,117.0059.44%26,323.0046.69%31,903.0054.94%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
TOTAL44,568.0083.39%54,118.0091.60%52,892.0093.81%54,394.0093.68%m
EQUITY
ord cap, reserves ord cap, reserves5,114.009.57%1,124.001.90%-68.00-0.12%4,360.007.51%m
prefs, minorities prefs, minorities3,764.007.04%3,839.006.50%3,557.006.31%-688.00-1.18%m
TOTAL8,878.0016.61%4,963.008.40%3,489.006.19%3,672.006.32%m
OTHER
NAV Basic- - - - 
NAV Diluted- - - - 

Glaxosmithkline Cash Flow Statement

%1$s Cash Flow Statement
31 Dec 2015 (GBP)31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)
Operating CF2,569.006,497.006,918.008,421.00m
Pre-Financing CF8,606.005,228.005,475.006,868.00m
Retained CF1,503.00-1,164.00-905.00479.00m

Glaxosmithkline Brokers

%1$s Brokers
NameActivityTypeMnemonicCode
Evolution Securities LimitedMarket Maker(MME)Broker/DealerEVOEVBGGB21MMT
Winterflood Securities LtdMarket Maker(MME)Broker/DealerWINSWNTSGB2LBIC
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

Finance Manila is owned and operated by ADVFN PLC.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:fm D:20191212 03:48:22